News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.

1Bitget UEX Daily | Iran Confirms Larijani's Death; “Cathie Wood” Bullish on AI; Micron Stock Hits New All-Time High (March 18, 2026)2Morgan Stanley exec says crypto ETF adoption still 'very early' as advisors weigh allocations3SOL price signal tied to previous 142% rally flashes again: Are the bulls back?

ProShares GENIUS ETF's $17B debut boosts case for tokenized money market funds
Cointelegraph·2026/02/23 17:09
Trump-Backed Stablecoin Briefly Slips as World Liberty Claims 'Coordinated Attack'
Decrypt·2026/02/23 17:07

BitMine Buys 51,000 ETH As Ethereum Co-Founder Vitalik Buterin Sells Again
Finviz·2026/02/23 17:06
SM Energy Announces Divestiture Agreement Worth $950 Million
Finviz·2026/02/23 17:06

Why Taboola (TBLA) Shares Are Falling Today
Finviz·2026/02/23 17:06

BTC Market Pulse: Week 9
Glassnode·2026/02/23 17:03

Engie eyes bitcoin mine and storage system at huge new Brazil solar plant
101 finance·2026/02/23 17:00

Top Crypto to Buy: Why BlockDAG, Arbitrum, Chainlink, and Avalanche Could Trigger the Next Market Surge
BlockchainReporter·2026/02/23 17:00
AI Fears Slam Online Travel Agency Stocks
Finviz·2026/02/23 17:00
Flash
00:08
Delphi Digital: Stablecoins may impact the bank interest margin model, with deposit outflow risks drawing attentionAccording to Odaily, Delphi Digital stated that compared to national security concerns, the potential impact of stablecoins on the traditional banking profit model is more direct. Currently, the yield on US Treasury bonds is about 3.89%, while the interest rate on ordinary savings accounts is about 0.39%. Banks earn interest rate spreads through deposits. It pointed out that stablecoins are also backed by assets such as Treasury bonds, and issuers are exploring mechanisms to distribute yields to holders. If this model is widely adopted, it could prompt funds to flow from the traditional banking system to stablecoins, thereby weakening banks' ability to obtain low-cost funds and provide credit.
00:06
Clinical trial results recognized by authoritative journal: Vaxcyte announces that the results of its phase 1/2 adult clinical trial for the pneumococcal conjugate vaccine Vax-31 have been officially published in the internationally renowned medical journal The Lancet Infectious Diseases.This study shows that Vax-31 demonstrated good safety and tolerability at all tested doses, while successfully inducing immune responses against 31 pneumococcal serotypes. **Breakthrough in Vaccine Design Overcomes Traditional Technical Limitations** Vax-31 was developed using Vaxcyte’s proprietary XpressCF™ cell-free protein synthesis technology platform, which offers significant technical advantages over traditional polysaccharide conjugate vaccines. This platform enables rapid and precise synthesis of highly purified vaccine antigens, avoiding the risk of cellular component contamination that may occur in traditional manufacturing processes. The clinical data published this time confirm that this technology platform can support the stable production of multivalent vaccines, laying a foundation for larger-scale clinical trials in the future. **Multivalent Vaccine Strategy Seizes Market Opportunities** Currently, the global pneumonia vaccine market is mainly dominated by Pfizer’s 13-valent pneumococcal conjugate vaccine Prevnar 13 and Merck’s 15-valent vaccine Vaxneuvance. Vax-31’s design covers 31 serotypes, offering broader protection than existing products. Analysts point out that if subsequent clinical trials proceed smoothly, Vax-31 is expected to submit a marketing application around 2028, seizing the initiative in the next-generation pneumonia vaccine market. **Capital Markets Focus on R&D Progress** Driven by this news, Vaxcyte’s stock price showed an upward trend in pre-market trading. Multiple investment institutions believe that the endorsement by an authoritative journal will significantly boost investor confidence in Vaxcyte’s technology platform. JPMorgan previously reported that Vaxcyte’s vaccine platform technology has differentiated advantages and recommended paying attention to its subsequent clinical progress.
00:06
HSBC reportedly considers significant layoffs in the coming years due to AI factors.格隆汇 March 19|HSBC Holdings Plc is planning large-scale layoffs in the coming years, with CEO Georges Elhedery betting on artificial intelligence to reduce the scale of its middle and back-office operations. This is one of the first significant signals of the technology reshaping Wall Street's employment landscape. According to sources who requested anonymity, non-client-facing positions in global service centers are expected to be most affected, and the relevant assessment is still at an early stage. One of the sources said that the adjustment could ultimately impact about 20,000 positions, accounting for approximately 10% of HSBC's total workforce.
News